Please view the latest news articles from across Europe below. Alternatively, filter by news category or search by keyword.
"We're now four years into the MErCuRIC project and have completed the first stage of our Phase I trial to identify a safe and tolerable dose of our novel combination therapy for CRC. The second stage of the Phase I trial is on-going, with patients currently being recruited in the UK, Belgium, Spain, France and Ireland. In parallel with our clinical work, the team has been working hard on developing genetic tests to identify the patients most likely to respond to the combination therapy and to allow doctors to monitor the therapy using blood tests rather than tissue biopsies. Our work is helping researchers and doctors to better understand CRC so that patients can be given tailored treatments most likely to succeed for their individual cancer."